38,179 Shares in Elevation Oncology, Inc. (NASDAQ:ELEV) Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new position in Elevation Oncology, Inc. (NASDAQ:ELEV) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 38,179 shares of the company’s stock, valued at approximately $103,000. XTX Topco Ltd owned approximately 0.07% of Elevation Oncology as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in shares of Elevation Oncology during the first quarter worth about $63,000. American Century Companies Inc. lifted its position in shares of Elevation Oncology by 55.7% in the second quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock worth $133,000 after buying an additional 17,602 shares in the last quarter. Rhumbline Advisers bought a new position in Elevation Oncology during the second quarter valued at approximately $175,000. Bank of New York Mellon Corp purchased a new position in Elevation Oncology during the 2nd quarter valued at approximately $415,000. Finally, Vanguard Group Inc. increased its stake in Elevation Oncology by 30.8% in the 1st quarter. Vanguard Group Inc. now owns 1,532,045 shares of the company’s stock worth $7,859,000 after acquiring an additional 360,799 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Elevation Oncology Trading Down 6.6 %

Shares of NASDAQ ELEV opened at $0.56 on Wednesday. Elevation Oncology, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $5.83. The company has a debt-to-equity ratio of 0.38, a quick ratio of 41.10 and a current ratio of 41.10. The company has a market cap of $30.62 million, a price-to-earnings ratio of -0.54 and a beta of 1.26. The business’s 50 day moving average price is $1.04 and its 200-day moving average price is $2.74.

Elevation Oncology (NASDAQ:ELEV) last released its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts expect that Elevation Oncology, Inc. will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

ELEV has been the topic of several recent research reports. Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Elevation Oncology in a research report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Elevation Oncology in a report on Wednesday, August 7th. Finally, JMP Securities restated a “market outperform” rating and set a $7.00 price target on shares of Elevation Oncology in a report on Monday, July 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.80.

Elevation Oncology Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.